An interventional study of Respiratory pathogen detection via molecular PCR and C-reactive protein (CRP) quantification in Asthma Acute and COPD Acute Exacerbation, sponsored by Université de Sherbrooke. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 429 studies in Asthma with a site in Canada — 42 open to participants now, 57 under way, 11 of them phase 3. Asthma · Canada.
Among the 429 studies in Asthma with a site in Canada, this one is the 154th largest by planned enrollment of the 367 interventional ones that give a count, is the only one that started in 2027, is one of 85 with no phase, reaches primary completion later than 47 of the 56 other live ones, and was the 429th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →42 of the 429 studies in Asthma with a site in Canada are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Canada, United States, Argentina and 1 more country
Ages 18+
AstraZeneca · Sites in Canada, United States, Argentina and 11 more countries
Ages 6+
University of British Columbia · Sites in Canada
Ages 19–80 · Healthy volunteers
University of Saskatchewan · Sites in Canada
Ages 18+ · Healthy volunteers
University of Alberta · Sites in Canada
Ages 18–55
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
429 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 105 · Phase 3 106 · Phase 4 59
First in 1998; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 110 across the 367 interventional studies, 104 across the 60 observational. Of the 342 that completed or were terminated, 147 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
228 of 429 have an industry lead sponsor. The 10 most frequent:
Université de Sherbrooke is the lead sponsor of 297 studies on the registry; 67 are open to participants now.
Université de Sherbrooke has 7 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
19 of the studies in Asthma with a site in Canada that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06785272Phase 3Suzanne SchuhMagnesium Trial in Acute Asthma in Emergency Department | 2027-10 |
| NCT06705764University of AlbertaTezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | 2026-11 |
Add all 19 to your calendar (.ics) → With an account.
Among the 429 studies in Asthma with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People with asthma or chronic obstructive pulmonary disease (COPD) often come to the emergency department because their breathing suddenly gets worse. These flare-ups are called exacerbations. Many of these episodes are caused by viruses or inflammation, not bacteria. However, clinicians still frequently prescribe antibiotics, even when they are unlikely to help. Unnecessary antibiotic use can cause side effects, increase healthcare costs, and contribute to antibiotic resistance, which is a growing public health problem.
The URGE study aims to find a better way to decide when antibiotics are truly needed during asthma or COPD attacks in the emergency department. The study will test whether using two rapid bedside tests can safely reduce unnecessary antibiotic prescriptions.
The first test is a rapid molecular test that looks for common respiratory viruses and certain bacteria using a nasopharyngeal swab. Results are available within about 15 to 20 minutes. The second test measures C-reactive protein (CRP) from a small blood sample. CRP is an inflammation marker that tends to be higher when a bacterial infection is present. Together, these tests give doctors quick information about whether an infection is likely viral, bacterial, or non-infectious.
URGE will recruit 200 adults who come to the emergency department with an asthma or COPD exacerbation to take part in the study. After providing consent, participants will be randomly assigned to one of two groups. In both groups, participants will complete both rapid tests. In one group, the test results will be shared with the treating doctor right away and can be used to help guide treatment decisions. In the other group, the doctor will not see the test results, and care will follow usual practice. Doctors will always be free to make their own clinical decisions, regardless of test results.
The main outcome the study will measure is whether or not patients are prescribed antibiotics when they leave the emergency department or are admitted to hospital. The study will also examine how long patients take antibiotics, hospital admissions, return visits to healthcare services, and patient satisfaction. Participants will be followed up by phone and through medical record review at 7 days and 30 days after their emergency visit to ensure they recover safely.
The URGE trial will study tests that are already approved and commonly used in healthcare. The goal is not to deny needed treatment, but to better match treatment to the cause of the flare-up. If successful, this approach could reduce unnecessary antibiotic use, improve patient care, and support safer, more sustainable treatment of asthma and COPD exacerbations in emergency departments.
Acute exacerbations of asthma and COPD are frequent causes of emergency department (ED) visits worldwide, with a substantial proportion of patients receiving antibiotics - often inappropriately - despite a likely viral or non-infectious etiology [1,2]. This practice contributes to antimicrobial resistance, patient harm, and unnecessary healthcare costs [3-8]. While guidelines emphasize the judicious use of antibiotics, real-time decision-making in the ED is often constrained by diagnostic uncertainty. Current approaches recommended by guidelines (GINA, GOLD, INESSS) rely heavily on symptom severity and do not systematically integrate host inflammatory or pathogen-specific data [9-12].
Leveraging evidence from previous randomized controlled trial post hoc analyses, the URGE trial is a pragmatic, randomized, open-label study designed to evaluate whether dual point-of-care testing (POCT) - combining rapid molecular microbial PCR (Polymerase Chain Reaction) testing and C-reactive protein (CRP) - can reduce antibiotic use in adults presenting to the ED with an asthma or COPD attack. This dual biomarker strategy aims to enhance diagnostic precision by integrating pathogen detection with host inflammatory responses, thereby guiding real-time, targeted decisions.
A total of 200 patients will be targeted, recruiting until at least 124 analysable patients have completed the trial. All participants will undergo microbial PCR and CRP testing after randomisation and will be managed in accordance with current clinical practice guidelines. In the intervention group, PCR and CRP results will be available to treating clinicians at the time of evaluation and used to inform management decisions. In the control group, test results will not be available to clinicians. The primary outcome is the proportion of patients prescribed antibiotics at ED discharge. Secondary outcomes include antibiotic duration, hospital admissions, revisit rates, and patient acceptability.
URGE is grounded in a growing body of evidence suggesting that either molecular microbial PCR alone or CRP can reduce antibiotic prescribing in acute respiratory illness. Molecular microbial POCT enables rapid identification of respiratory pathogens, whereas CRP reflects the host's systemic inflammatory response - particularly in response to bacterial infections- thereby facilitating early exclusion of a bacterial etiology. However, to date, no randomized trials have assessed the combined impact of these two complementary biomarkers in a real-world emergency care setting. URGE is the first study to evaluate whether integrating both markers into a unified triage strategy can synergistically improve antibiotic stewardship in patients with asthma and COPD attacks.
If successful, the URGE trial will pave the way for a biomarker-guided, proactive approach to antibiotic stewardship in acute airway disease, shifting ED management from a "treat all" paradigm to one that integrates real-time microbial identification by PCR and CRP-based inflammatory profiling. This study will inform the design of larger multicenter implementation trials and help transform care for respiratory infections in the ED.
This protocol is reported in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2025 reporting guideline [13].
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For COPD: post-bronchodilator FEV1/FVC \<0.70 or below the LLN with ≥10 pack-years smoking history and compatible symptoms, consistent with GOLD 2026.
*Patients with physician-diagnosed disease, without objective testing, may undergo confirmatory testing \< 3 months after URGE trial participation to confirm eligibility.
Exclusion Criteria:
Medical conditions
Logistical or Operational Exclusions
Other exclusions
-Individuals are accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalised.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dual POCT results (multiplex PCR + CRP) are disclosed in real time to the treating physician, together with a predefined advisory PCR+CRP antibiotic algorithm; results are communicated to the patient. Clinicians may override the algorithm.
Diagnostic Test: Respiratory pathogen detection via molecular PCR · Diagnostic Test: C-reactive protein (CRP) quantification · Other: Disclosure of dual POCT results with advisory PCR+CRP algorithm
Participants undergo the same dual POCT (PCR + CRP) under identical conditions, but results are not disclosed to the treating physician or the participant during the index visit. Usual care per clinician judgment.
Diagnostic Test: Respiratory pathogen detection via molecular PCR · Diagnostic Test: C-reactive protein (CRP) quantification
Rapid, point-of-care (POC) tests at the ED visit
Also known as: BIOFIRE® SPOTFIRE® Respiratory Panel
Rapid, point-of-care (POC) tests at the ED visit.
Also known as: Afinion™ CRP
Multiplex PCR and CRP results are disclosed in real time to the treating physician (written note in the EMR triage section), together with a predefined advisory antibiotic algorithm. Results are communicated to the patient by the treating physician. Clinicians may override the algorithm at any time.
Proportion of participants prescribed antibiotics at ED discharge
Prescription of any antibiotic at ED discharge
Time frame: At ED discharge or hospital admission (assessed up to 5 days)
Proportion of patients receiving only a single dose of antibiotics
Single-dose antibiotic administration
Time frame: During ED stay (assessed up to 5 days)
Proportion of patients receiving intravenous (IV) antibiotics
Intravenous antibiotic administration during ED stay
Time frame: During ED stay (assessed up to 5 days)
Total duration of oral antibiotic use
Number of days of oral antibiotic therapy
Time frame: From initiation to discontinuation (assessed up to 30 days)
Total duration of IV antibiotic use
Number of days of intravenous antibiotic therapy
Time frame: During ED stay and/or hospitalization (assessed up to 30 days)
Antibiotic prescription after ED discharge
New antibiotic prescriptions after discharge for patients who did not receive one at discharge, and the time until that prescription was issued.
Time frame: Day 7 and Day 30
ED length of stay
Hours from ED registration to discharge or admission order
Time frame: From ED registration to ED discharge or admission order (assessed up to 5 days)
Hospital admission rate
Admission to hospital after ED evaluation
Time frame: During index ED visit (assessed up to 5 days)
Length of hospital stay
Duration from hospital admission to discharge
Time frame: From hospital admission to discharge (assessed up to 30 days)
Corticosteroid prescribing at ED discharge
Prescription of systemic corticosteroids
Time frame: At ED discharge (assessed up to 5 days)
Oseltamivir prescribing at ED discharge
Oseltamivir prescription in PCR-confirmed influenza
Time frame: At ED discharge (assessed up to 5 days)
Time to oseltamivir initiation
Time from randomization to first oseltamivir dose in PCR-confirmed influenza
Time frame: From randomization to first oseltamivir dose (assessed up to 30 days)
Duration of oseltamivir use
Number of days of oseltamivir treatment in PCR-confirmed influenza
Time frame: Through Day 30 follow-up
Isolation precautions applied (mask) during ED stay
Participants with documented initiation of respiratory isolation precautions (mask use) at any time during the ED stay.
Time frame: During ED stay, from ED arrival to ED discharge (assessed up to 5 days)
Adverse events (AEs)
Proportion of participants with ≥1 adverse event (AE) and ≥1 serious adverse event (SAE). Severity according to CTCAE v5.0 (mild, moderate, severe).
Time frame: Index ED visit, Day 7, and Day 30 follow-up
In-hospital mortality
Death occurring during the index ED visit or during the subsequent index hospitalization (if admitted). Reported as all-cause and asthma/COPD-related.
Time frame: Index ED visit and index hospital admission, up to discharge (assessed up to 30 days)
Unscheduled primary care consultation
Any unplanned primary care visits after the index ED encounter. Reported as all-cause and asthma/COPD-related.
Time frame: Day 7 and Day 30 follow-up.
Unscheduled ED visits
Return visits to any ED after the index encounter. Reported as all-cause and asthma/COPD-related
Time frame: Day 7 and Day 30 follow-up
Unscheduled hospital admission
Any unplanned hospital admission after the index encounter. Reported as all-cause and asthma/COPD-related
Time frame: Day 7 and Day 30 follow-up
Mortality (all-cause and asthma/COPD-related)
Death after the index ED visit, reported as all-cause and asthma/COPD-related
Time frame: Day 7 and Day 30 follow-up
Time to obtain POCT PCR results
Time from documented sample collection to PCR result availability on the POCT platform (device timestamp and/or documented availability for disclosure)
Time frame: Index ED visit (assessed up to 5 days)
Time to obtain POCT CRP results
Time from documented sample collection to CRP result availability on the platform (device timestamp and/or documented availability for disclosure)
Time frame: Index ED visit (assessed up to 5 days)
Prevalence and distribution of respiratory viruses and bacteria detected
Pathogen type detected by PCR
Time frame: Index ED visit (assessed up to 5 days)
Prevalence of influenza virus detected
PCR-confirmed influenza detection
Time frame: Index ED visit (assessed up to 5 days)
Antibiotic decision-POCT concordance
Algorithm-recommended antibiotic decision (discourage / consider / recommend) derived from the predefined CRP+PCR algorithm; and observed antibiotic prescribing status at ED discharge (yes/no), cross-classified with POCT profile (CRP strata and PCR result categories).
Time frame: At ED discharge (assessed up to 5 days)
Antibiotic prescribing based on CRP strata
CRP level category (\<20, 20-40, \>40 mg/L)
Time frame: At ED discharge (assessed up to 5 days)
Time to antibiotic initiation
Time from randomization to first antibiotic administration (IV or oral)
Time frame: From randomization to first antibiotic dose (assessed up to 30 days)
Atypical pathogen-targeted antibiotic (e.g. macrolide) use among participants with positive PCR for atypical bacteria.
Initiation of an atypical pathogen-targeted antibiotic (e.g. macrolide) among participants with PCR-detected atypical bacteria
Time frame: During ED stay (assessed up to 5 days)
Patient satisfaction and acceptability of POCT strategy
Patient-reported satisfaction
Time frame: At ED visit (assessed up to 5 days)
POCT-Laboratory PCR concordance
Concordance between POCT PCR results and routine laboratory results when both are performed during the index ED visit
Time frame: At ED visit (assessed up to 5 days)
Plan to share: Yes — De-identified individual participant data (IPD) will be shared for all participants who consent to third-party data sharing. This includes the data underlying the published results: baseline demographic and clinical characteristics, eligibility variables, randomization arm, point-of-care test results (multiplex PCR and CRP), intervention adherence (POCT disclosure and algorithm concordance), primary and secondary outcomes (antibiotic prescribing, healthcare utilization, mortality), and adverse events. A complete data dictionary will be provided with the dataset. Data will be coded with study IDs, and all direct identifiers will be removed to prevent re-identification.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Beginning after publication of the primary outcome results and available for at least 15 years thereafter.
Access criteria: Researchers must submit a research proposal to the study investigators. Access requires approval by the investigators, a signed data-sharing agreement, and ethics approval where applicable. Data will be provided through a controlled-access repository at Université de Sherbrooke.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.
Of 599 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 23 months is close to that.
Counting every sponsor, half of 649 studies reached it within 23 months; a quarter within 10 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.